Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition (OTCQB: ADIA) announced IRB approval and a ClinicalTrials.gov submission on May 5, 2026 for a randomized, controlled study testing its AdiaVita stem cell and exosome therapy plus glutathione in adults with Stage 2–4 chronic kidney disease (CKD).
The trial will assess safety and track eGFR, serum creatinine, and inflammatory biomarkers; recruitment begins upon ClinicalTrials.gov acceptance.
Adia Nutrition (OTCQB: ADIA) reported IRB progress on three pivotal clinical studies: Lower Back Pain, Georgia Autism, and Kidney Study. The company received second-round IRB comments for the first two trials and first-round comments for the Kidney Study, and says final IRB approval is expected soon.
Adia plans to register all three studies on ClinicalTrials.gov and begin recruitment immediately after final IRB approval.
Adia Nutrition (OTCQB: ADIA) is seeking to acquire a larger property to expand its flagship Adia Med clinic in Winter Park, Florida, to increase patient capacity, research space, and introduce potential insurance-billable wound care and orthopedic services.
Q1 2026 momentum includes revenue growth to approximately $700,508 (from $6,380 in 2024), IRB progress on a lower back pain trial, plans for four-to-five new studies in 2026, an April 8 partnership with an Atlanta clinic, Form 10 effectiveness in February 2026, and a corporate name change to Adia Med announced April 15, 2026.
Adia Nutrition (OTCQB: ADIA) is rebranding to Adia Med, Inc. to reflect a shift to regenerative medicine, stem cell therapies, and biologic products. The company operates Adia Med clinics and Adia Labs, has an effective Form 10, and requested SIC code 2836 to align revenue classification with biologic products.
The name change is expected to complete in the coming months, subject to customary regulatory approvals; the ticker ADIA is expected to remain unchanged.
Adia Nutrition (OTCQB: ADIA) announced a strategic partnership with a leading Atlanta clinic to supply regenerative products for a new Autism Spectrum Disorder clinical study. The trial will enroll 100 participants, each receiving 3 infusions of AdiaVita (total 300 infusions); a single infusion is noted at about $8,000 as a price benchmark. Adia Med of Winter Park is separately recruiting for its own autism study starting May 2026. Adia Labs products are limited to research or IRB-approved studies and meet stated FDA quality and donor standards.
Adia Nutrition (OTCQB: ADIA) reported fiscal 2025 results and a strategic shift into regenerative medicine. Revenue rose to $700,508 from $6,380 in 2024, with gross profit of $191,670. The company recorded an operating loss of $366,492 and net loss of $395,464 and disclosed going-concern doubt.
Adia achieved full SEC reporting status in February 2026 and operates divisions Adia Med, Adia Labs, and Biolete while investing in R&D, clinical services, and infrastructure.
Adia Nutrition (OTCQB: ADIA) will host a live Zoom presentation tonight, March 24, 2026 at 6:00 PM EDT, with UCF CARD to explain an ongoing 24-month, IRB-approved clinical study (ClinicalTrials.gov ID: NCT07304440).
The trial is recruiting children ages 3–12 with autism and evaluates AdiaVita umbilical cord blood-derived stem cells and exosomes plus glutathione. Registration is free via Eventbrite and contact details are provided for enrollment and partnership inquiries.
Adia Nutrition (OTCQB: ADIA) appointed Amy Dalrymple, MSN, APRN, FNP-C, to lead its new Regenerative Aesthetics Division at Adia Med of Winter Park.
Dalrymple brings 11 years in aesthetic medicine; services launch with an open house on March 30, 2026 and patient treatments begin April 6, 2026.
Appointments, consultations, and licensing inquiries are available via adianutrition.com and adiamed.com or by phone at 321-788-0850.
Adia Med (OTCQB: ADIA) relaunched its website with ZenChange Marketing to centralize clinical research information, study summaries, enrollment details, and social media management. A highlighted initiative is the Autism Stem Cell Clinical Study (NCT07304440), a 24-month investigational trial with active recruitment and a one-time participation cost of $12,000.
The interventional phase is anticipated to begin in May 2026. The organization emphasizes investigational status, informed consent, medical oversight, and participant safety while using a patient-pay model without grants or government funding.
Adia Nutrition (OTCQB: ADIA) announced that subsidiary Adia Med submitted a final revised protocol to the Institutional Review Board on March 3, 2026, for a lower back pain study of AdiaVita.
The trial is a single-blind, placebo-controlled IV study randomizing ~100 participants with a three-month initial treatment and a crossover phase; patient-pay remains $5,000 per participant.